Review Article | Published:

Cardiorenal complications of immune checkpoint inhibitors

Nature Reviews Nephrologyvolume 14pages571588 (2018) | Download Citation

Abstract

The development of immune checkpoint inhibitors (ICIs) has driven a revolutionary change in cancer treatment. Although traditional chemotherapeutic agents remain the first-line option for most cancers, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These agents target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. Clinical studies have demonstrated these immunotherapeutics to elicit favourable antitumour responses in a variety of chemotherapy-refractory malignancies. However, use of these agents can also induce immune-related adverse events (irAEs) in off-target organs, including the heart and kidney. The most common manifestations of heart and kidney damage are myocarditis and acute interstitial nephritis, respectively, but other manifestations have been reported and, although rare, these off-target effects can be life threatening. Available data suggest that ICIs induce their off-target effects through several mechanisms, including direct binding to cell surface proteins expressed in healthy tissue, activation of T cells that cross-react with off-target tissues, generation of autoantibodies or by increasing levels of pro-inflammatory cytokines. Greater understanding of the adverse effects of cancer immunotherapies and the underlying mechanisms will facilitate the development of biomarkers to identify at-risk patients and approaches to prevent these irAEs.

Key points

  • Tumours use immune checkpoint pathways including programmed cell death protein 1 (PD-1)-mediated and cytotoxic T lymphocyte antigen 4 (CTLA4)-mediated pathways to evade recognition and destruction by the host immune system.

  • Immune checkpoint inhibitors (ICIs) target these checkpoint pathways and re-programme the host immune system to activate an antitumour immune response.

  • The use of ICIs is rapidly expanding for a variety of cancers owing to their established clinical efficacy; however, they are associated with a variety of immune-mediated injuries in different organs, including the kidney and heart.

  • Immune-mediated kidney injury with ICIs most commonly manifests as acute interstitial nephritis, although other patterns of renal injury have also been described; early treatment with corticosteroids typically reverses kidney injury.

  • Cardiac effects of ICIs are highly variable, but myocarditis is the most reported form of ICI-associated cardiotoxicity; this cardiotoxicity is generally reversible with corticosteroids, but fatal steroid-resistant cases have been reported.

  • Biomarker development and improved understanding of the mechanisms of immune-related adverse events will be crucial to aid early diagnosis and develop targeted treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004).

  2. 2.

    Menke, J. et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J. Immunol. 179, 7466–7477 (2007).

  3. 3.

    Burnet, M. Cancer; a biological approach. I. The processes of control. Br. Med. J. 1, 779–786 (1957).

  4. 4.

    Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329–333 (1982).

  5. 5.

    Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1–27 (1970).

  6. 6.

    Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183, 534–536 (1974).

  7. 7.

    Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998).

  8. 8.

    van den Broek, M. E. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781–1790 (1996).

  9. 9.

    Engels, E. A. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306, 1891–1901 (2011).

  10. 10.

    Hall, E. C., Pfeiffer, R. M., Segev, D. L. & Engels, E. A. Cumulative incidence of cancer after solid organ transplantation. Cancer 119, 2300–2308 (2013).

  11. 11.

    Suranyi, M. G. et al. Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 66, 655–661 (1998).

  12. 12.

    MacKie, R. M., Reid, R. & Junor, B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348, 567–568 (2003).

  13. 13.

    Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).

  14. 14.

    Murakami, N., Motwani, S. & Riella, L. V. Renal complications of immune checkpoint blockade. Curr. Problems Cancer 41, 100–110 (2017).

  15. 15.

    Weber, J. Immune checkpoint proteins: a new therapeutic paradigm for cancer — preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37, 430–439 (2010).

  16. 16.

    Appleman, L. J., van Puijenbroek, A. A., Shu, K. M., Nadler, L. M. & Boussiotis, V. A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168, 2729–2736 (2002).

  17. 17.

    Boise, L. H. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3, 87–98. J. Immunol. 185, 3788–3799 (2010).

  18. 18.

    Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005).

  19. 19.

    Ward, S. G., Westwick, J., Hall, N. D. & Sansom, D. M. Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur. J. Immunol. 23, 2572–2577 (1993).

  20. 20.

    Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).

  21. 21.

    Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010).

  22. 22.

    Riella, L. V., Paterson, A. M., Sharpe, A. H. & Chandraker, A. Role of the PD-1 pathway in the immune response. Am. J. Transplant. 12, 2575–2587 (2012).

  23. 23.

    Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3 — potential mechanisms of action. Nat. Rev. Immunol. 15, 45–56 (2015).

  24. 24.

    Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).

  25. 25.

    Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 98, 13866–13871 (2001).

  26. 26.

    Sheppard, K. A. et al. PD-1 inhibits T cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574, 37–41 (2004).

  27. 27.

    Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945–954 (2004).

  28. 28.

    Linsley, P. S. et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4, 535–543 (1996).

  29. 29.

    Vandenborre, K. et al. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T cell activation. Immunology 98, 413–421 (1999).

  30. 30.

    Fallarino, F., Fields, P. E. & Gajewski, T. F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188, 205–210 (1998).

  31. 31.

    Downey, J. TCR/CD3 mediated stop-signal is decoupled in T cells from Ctla4 deficient mice. Immunol. Lett. 115, 70–72 (2008).

  32. 32.

    Schneider, H., Smith, X., Liu, H., Bismuth, G. & Rudd, C. E. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur. J. Immunol. 38, 40–47 (2008).

  33. 33.

    Krummel, M. F. & Allison, J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533–2540 (1996).

  34. 34.

    Rudd, C. E., Taylor, A. & Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12–26 (2009).

  35. 35.

    Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).

  36. 36.

    Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411–417 (1997).

  37. 37.

    Yamaguchi, T. et al. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc. Natl Acad. Sci. USA 110, E2116–E2125 (2013).

  38. 38.

    Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999).

  39. 39.

    Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319–322 (2001).

  40. 40.

    Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477–1483 (2003).

  41. 41.

    Salama, A. D. et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198, 71–78 (2003).

  42. 42.

    Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691–10696 (2004).

  43. 43.

    Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547 (1995).

  44. 44.

    Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988 (1995).

  45. 45.

    Paterson, A. M. et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 212, 1603–1621 (2015).

  46. 46.

    Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl Acad. Sci. USA 113, E2383–E2392 (2016).

  47. 47.

    Prokunina, L. et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666–669 (2002).

  48. 48.

    Huang, C. H. et al. Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology (Oxford) 50, 1809–1813 (2011).

  49. 49.

    Barreto, M. et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur. J. Hum. Genet. 12, 620–626 (2004).

  50. 50.

    Ueda, H. et al. Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511 (2003).

  51. 51.

    Vaidya, B. et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford) 41, 180–183 (2002).

  52. 52.

    Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).

  53. 53.

    Dong, H. et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).

  54. 54.

    Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).

  55. 55.

    Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327–1337 (2009).

  56. 56.

    Nazareth, M. R. et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178, 5552–5562 (2007).

  57. 57.

    Han, Y. et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59, 567–579 (2014).

  58. 58.

    Liakou, C. I. et al. CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987–14992 (2008).

  59. 59.

    Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

  60. 60.

    Hodi, F. S. et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 17, 1558–1568 (2016).

  61. 61.

    Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004–2012 (2015).

  62. 62.

    Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

  63. 63.

    Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

  64. 64.

    Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

  65. 65.

    Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

  66. 66.

    Yearley, J. H. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin. Cancer Res. 23, 3158–3167 (2017).

  67. 67.

    Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

  68. 68.

    Kwon, E. D. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA 94, 8099–8103 (1997).

  69. 69.

    Shrikant, P., Khoruts, A. & Mescher, M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483–493 (1999).

  70. 70.

    Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).

  71. 71.

    Perazella, M. & Shirali, A. Nephrotoxicity of cancer immunotherapies: past, present and future. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.2018050488 (2018).

  72. 72.

    Izzedine, H. et al. Renal effects of immune checkpoint inhibitors. Nephrol. Dial. Transplant. 32, 936–942 (2017).

  73. 73.

    Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638–647 (2016).

  74. 74.

    Shirali, A. C., Perazella, M. A. & Gettinger, S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am. J. Kidney Dis. 68, 287–291 (2016).

  75. 75.

    Izzedine, H. et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769–773 (2014).

  76. 76.

    Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211–212 (2009).

  77. 77.

    Kidd, J. M. & Gizaw, A. B. Ipilimumab-associated minimal-change disease. Kidney Int. 89, 720 (2016).

  78. 78.

    Kitchlu, A. et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am. J. Kidney Dis. 70, 581–585 (2017).

  79. 79.

    Ray, A., Ghosh, S., Ghosh, M. & Yarlagadda, S. Nivolumab induced renal failure with collapsing focal segmental glomerulosclerosis (FSGS). J. Am. Soc. Nephrol. 27, 1010A (2016).

  80. 80.

    Lin, J., Schiff, M., Salvatore, S., Shoustari, A. & Glezerman, I. Membranous nephropathy related to the checkpoint inhibitor nivolumab. J. Am. Soc. Nephrol. 27, 102A (2016).

  81. 81.

    Murakami, N., Borges, T. J., Yamashita, M. & Riella, L. V. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin. Kidney J. 9, 411–417 (2016).

  82. 82.

    Daanen, R. A. et al. Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report. J. Immunother. 40, 345–348 (2017).

  83. 83.

    Nolan, E. et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl Med. 9, eaal4922 (2017).

  84. 84.

    Tarrio, M. L., Grabie, N., Bu, D. X., Sharpe, A. H. & Lichtman, A. H. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 188, 4876–4884 (2012).

  85. 85.

    Lucas, J. A. et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181, 2513–2521 (2008).

  86. 86.

    Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T cell mediated injury in the heart. Circulation 116, 2062–2071 (2007).

  87. 87.

    Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

  88. 88.

    Eggermont, A. M. et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

  89. 89.

    Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).

  90. 90.

    Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).

  91. 91.

    Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).

  92. 92.

    Gibson, R., Delaune, J., Szady, A. & Markham, M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. https://doi.org/10.1136/bcr-2016-216228 (2016).

  93. 93.

    Yun, S., Vincelette, N. D., Mansour, I., Hariri, D. & Motamed, S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep. Oncol. Med. 2015, 794842 (2015).

  94. 94.

    Dasanu, C. A., Jen, T. & Skulski, R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J. Oncol. Pharm. Pract. 23, 231–234 (2017).

  95. 95.

    Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E. & Schwartz, D. R. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J. Immunother. Cancer 3, 4 (2015).

  96. 96.

    Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).

  97. 97.

    Norwood, T. G. et al. Smoldering myocarditis following immune checkpoint blockade. J. Immunother. Cancer 5, 91 (2017).

  98. 98.

    Loffler, A. I. & Salerno, M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J. Nucl. Cardiol. https://doi.org/10.1007/s12350-018-1293-9 (2018).

  99. 99.

    Friedrich, M. G. et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J. Am. Coll. Cardiol. 53, 1475–1487 (2009).

  100. 100.

    Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B. & Moslehi, J. J. Cardiovascular toxicities associated with cancer immunotherapies. Curr. Cardiol. Rep. 19, 21 (2017).

  101. 101.

    Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017).

  102. 102.

    Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl Med. 6, 230ra45 (2014).

  103. 103.

    Caturegli, P. et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225–3235 (2016).

  104. 104.

    Ding, H., Wu, X. & Gao, W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin. Immunol. 115, 184–191 (2005).

  105. 105.

    Spanou, Z. et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J. Am. Soc. Nephrol. 17, 2919–2927 (2006).

  106. 106.

    Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).

  107. 107.

    Abraham, C. & Cho, J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1090–1100 (2009).

  108. 108.

    Krebs, C. F. et al. T helper type 17 cells in immune-mediated glomerular disease. Nat. Rev. Nephrol. 13, 647–659 (2017).

  109. 109.

    Osorio, J. C. et al. Antibody-mediated thyroid dysfunction during T cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28, 583–589 (2017).

  110. 110.

    Shi, H. et al. Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. Arthritis Res. Ther. 19, 52 (2017).

  111. 111.

    Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715–720 (2018).

  112. 112.

    Belliere, J. et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br. J. Cancer 115, 1457–1461 (2016).

  113. 113.

    Jung, K., Zeng, X. & Bilusic, M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 17, 188 (2016).

  114. 114.

    Forde, P. M., Rock, K., Wilson, G. & O’Byrne, K. J. Ipilimumab-induced immune-related renal failure — a case report. Anticancer Res. 32, 4607–4608 (2012).

  115. 115.

    Bottlaender, L. et al. Acute interstitial nephritis after sequential ipilumumab — nivolumab therapy of metastatic melanoma. J. Immunother. Cancer 5, 57 (2017).

  116. 116.

    Escandon, J. et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J. Immunother. Cancer 5, 3 (2017).

  117. 117.

    Thajudeen, B., Madhrira, M., Bracamonte, E. & Cranmer, L. D. Ipilimumab granulomatous interstitial nephritis. Am. J. Ther. 22, e84–e87 (2015).

  118. 118.

    Laubli, H. et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer 3, 11 (2015).

Download references

Reviewer information

Nature Reviews Nephrology thanks I. Glezerman, D. Leaf and the other, anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Affiliations

  1. Section of Nephrology, Yale University School of Medicine, New Haven, CT, USA

    • Krishna Sury
    • , Mark A. Perazella
    •  & Anushree C. Shirali
  2. VA Medical Center, West Haven, CT, USA

    • Mark A. Perazella

Authors

  1. Search for Krishna Sury in:

  2. Search for Mark A. Perazella in:

  3. Search for Anushree C. Shirali in:

Contributions

All authors researched data for the article and contributed to writing the review and editing the manuscript before submission.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Anushree C. Shirali.

Glossary

T helper 1 (TH1) cells

Differentiated population of T cells that provide antibacterial and antiviral immunity. They are characterized by expression of the transcription factors signal transducer and activator of transcription 4 (STAT4)–T-box transcription factor TBX21 (also known as TBET) and production of IFNγ, IL-2 and tumour necrosis factor (TNF).

TH2 cells

Differentiated population of T cells that provide antiparasitic immunity and tissue repair and mediate allergic diseases such as asthma. They are characterized by expression of the transcription factors signal transducer and activator of transcription 6 (STAT6)–trans-acting T cell-specific transcription factor GATA3 and by the production of IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25.

Regulatory T (Treg) cells

Specialized subset of T lymphocytes characterized by the expression of CD4 and CD25 as well as the transcription factor forkhead box protein P3. These cells suppress the activation, proliferation and cytokine production of CD4+ and CD8+ T cells via cytokines such as IL-10 and transforming growth factor-β (TGFβ).

Langerhans cells

DCs found specifically in the epidermis.

Microclusters

Complex structure of the T cell receptor and antigen-presenting cell with major histocompatibility complex-bound antigen along with co-stimulatory and signalling molecules. This structure is thought to promote T cell activation by providing sustained signalling.

Tumour-draining DCs

Dendritic cells (DCs) found in the draining lymph nodes of tumours. These DCs can process tumour antigen and subsequently activate T cells that are specific for these antigens.

Acute interstitial nephritis

(AIN). The pathologic description given to the influx of mononuclear immune cells including lymphocytes, macrophages and eosinophils into the interstitium and peritubular regions of the kidney. Clinically, AIN results in acute kidney injury and can result from an inflammatory reaction to drugs or to infections including viruses and bacteria.

Granuloma

Aggregate of histiocytes, lymphocytes, plasma cells and eosinophils that form in tissues including the kidney in response to viral infection or autoimmune disease.

Hypophysitis

Inflammation of the pituitary gland.

Sterile pyuria

Appearance of white blood cells in the urine without growth of microorganisms in urine culture to suggest an infectious aetiology.

White blood cell casts

Microscopic cylindrical structures formed by the accumulation of white blood cells and protein within the lumen of kidney tubules. These casts can slough off into urine and may be detected on microscopy of urine sediment.

Bland urine sediment

Absence of cells or cellular casts in the urine.

Ileitis

Inflammation of the ileum, the terminal component of the small intestine, due to drugs, infection or autoimmune disease.

Sialadenitis

Inflammation of the salivary glands.

Iritis

Form of anterior uveitis characterized by inflammation of the iris, the middle part of the uvea, which surrounds the pupil.

Pyuria

Presence of white blood cells in urine.

Myocarditis

Inflammation of the myocardium due to infection, drug reaction or ischaemia.

Myositis

Inflammation of muscle due to infection, injury or drugs.

Troponin I

Inhibitory subunit of the myocardial troponin complex that is released from the myocardium following myocardial infarction or other injury. Troponin I serves as a specific biomarker for cardiac injury.

P–R interval

Time period between atrial repolarization and ventricular repolarization, measured on an electrocardiogram between the beginning of the P wave until the beginning of the QRS complex.

ST-segment depression

Electrocardiogram pattern seen in myocardial ischaemia that represents a defect in ventricular depolarization and repolarization. It is characterized by a down-sloping segment instead of the usual flat line between the S and T waves.

Right bundle branch block

Pattern on electrocardiogram characterized by delayed depolarization of the right ventricle, resulting in aberrant waves such as a widened QRS complex and terminal R wave in lead V1. Right bundle branch block may indicate the presence of underlying cardiac ischaemia.

Creatine kinase-muscle/brain

(CK-MB). Isozyme of creatine kinase that is abundantly found in the heart and to a lesser degree in skeletal muscle. Similar to troponin I, CK-MB is released into the systemic circulation within hours of myocardial injury but decreases to normal levels within 24–48 hours.

Hypokinesis

Decreased wall motion on transthoracic electrocardiogram reflecting weakened myocardial muscle.

Akinesis

Failure of the ventricles of the heart to fully contract, which is seen as localized or global lack of wall motion on transthoracic electrocardiogram.

T1-weighted

Type of MRI in which only longitudinal movement of protons is measured. Images are characterized by fat appearing white, which is ideal for anatomical analysis.

T2-weighted

Type of MRI in which only transverse movement of protons is measured. Images are characterized by fat and water appearing white, which detects pathology such as infection or tumour.

Type II hypersensitivity

Immune reaction caused by antigen–antibody complexes that activate the complement system and cause cell lysis.

Type IV hypersensitivity

Immune reaction caused by activation of antigen-specific T cells by dendritic cells. The effector function of these cells includes direct cytotoxicity or cytokine release, which mediates cell or tissue injury.

Drug-specific T cells

T cells that become activated when they recognize a specific peptide in drugs, either directly or via cross reactivity. These T cells can circulate and infiltrate various tissues, causing inflammatory injury.

Drug-specific lymphocyte proliferation tests

Also known as the lymphocyte tolerance test; an in vitro assay that examines T cell proliferation and/or cytokine release in response to stimulation with specific drugs.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41581-018-0035-1